In vitro assessment of the gastrointestinal transit tolerance of taxonomic reference strains from human origin and probiotic product isolates of Bifidobacterium.
Next to health promoting effects, the functional aspect of probiotic strains also involves their capacity to reach the colon as viable metabolically active cells. The present study aimed to assess the potential of 24 probiotic product isolates and 42 human reference strains of Bifidobacterium to survive gastrointestinal transit under in vitro conditions. The survival capacity of exponential and stationary phase cultures upon exposure to gastric and small intestinal juices was determined using a recently developed microplate-based assay in combination with the LIVE/DEAD BacLight Bacterial Viability kit. All 66 strains tested displayed a considerable loss in viability during exposure to an acidic pepsin containing solution (pH 2.0). Among the 10 taxa tested, cultures of B. animalis ssp. lactis appeared to be most capable to survive gastric transit. Although to a lesser extent, the presence of bile salts also affected the viability of most of the strains tested. Except for 3 strains, all 66 strains showed bile salt hydrolase activity using an agar-based assay. In contrast, the bifidobacterial strains used in this study appeared to possess a natural ability to survive the presence of pancreatin (pH 8.0). Although the effect was not significant, a slightly enhanced tolerance to gastrointestinal transit was observed when cells were in the stationary phase, especially when exposed to acid, compared with cells being in the exponential phase. Survival in the gastrointestinal tract appeared to be largely strain-dependent and hence implies that different strains will likely display a different behavior in functionality. The assay used in this study allows an initial assessment of strains for use as probiotic cultures prior to selecting potential candidate strains for further investigation in vivo.
Masco
L
L
Laboratory of Microbiology, Ghent University, K. L. Ledeganckstraat 35, B-9000 Gent, Belgium. Liesbeth_Masco@innogenetics.com
Crockaert
C
C
Van Hoorde
K
K
Swings
J
J
Huys
G
G
D000581:Amidohydrolases / Q000032:analysis / Q000378:metabolism; D000818:Animals; D001644:Bifidobacterium / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology*; D001647:Bile Acids and Salts / Q000378:metabolism / Q000494:pharmacology*; D005750:Gastric Juice / Q000737:chemistry / Q000201:enzymology / Q000382:microbiology*; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D041981:Gastrointestinal Tract / Q000737:chemistry / Q000382:microbiology*; D005772:Gastrointestinal Transit / Q000502:physiology; D006801:Humans; D010194:Pancreatin / Q000378:metabolism / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism / Q000494:pharmacology; D019936:Probiotics; D016019:Survival Analysis; D013997:Time Factors
D001647:Bile Acids and Salts; D005765:Gastrointestinal Agents; D010194:Pancreatin; D010434:Pepsin A; D000581:Amidohydrolases; C023154:choloylglycine hydrolase